Andere talen Theratechnologies Inc.

Aandelen

TH

CA88338H7040

Beurs gesloten - Toronto S.E. Andere beurzen 21:59:50 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,8 ^CAD	-2,70%		-0,55%	-15,89%

10/04	Update over Theratechnologies; meer dan 5% lager op TSX na kleiner nettoverlies in Q1, in afwachting van besluit FDA	MT
10/04	Theratechnologies stijgt bijna 6% op de Amerikaanse premarket na een kleiner nettoverlies in het eerste kwartaal en een versnelde fase 1-studie voor een medicijn tegen eierstokkanker	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders	15/04
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	11/04
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	10/04
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	10/04
Theratechnologies: Fiscal Q1 Earnings Snapshot	10/04
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	10/04
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	10/04
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	10/04
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024	10/04
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	10/04
North American Morning Briefing : Traders Await -2-	10/04
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform	08/04
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	08/04
Theratechnologies Appoints Elina Tea to its Board of Directors	05/04
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	05/04
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update	03/04
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	28/03
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	28/03
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform	28/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Theratechnologies Inc.

Aandelen

TH

CA88338H7040

Andere talen

Filters